Nature Communications (May 2016)
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
- James E. Robinson,
- Kathryn M. Hastie,
- Robert W. Cross,
- Rachael E. Yenni,
- Deborah H. Elliott,
- Julie A. Rouelle,
- Chandrika B. Kannadka,
- Ashley A. Smira,
- Courtney E. Garry,
- Benjamin T. Bradley,
- Haini Yu,
- Jeffrey G. Shaffer,
- Matt L. Boisen,
- Jessica N. Hartnett,
- Michelle A. Zandonatti,
- Megan M. Rowland,
- Megan L. Heinrich,
- Luis Martínez-Sobrido,
- Benson Cheng,
- Juan C. de la Torre,
- Kristian G. Andersen,
- Augustine Goba,
- Mambu Momoh,
- Mohamed Fullah,
- Michael Gbakie,
- Lansana Kanneh,
- Veronica J. Koroma,
- Richard Fonnie,
- Simbirie C. Jalloh,
- Brima Kargbo,
- Mohamed A. Vandi,
- Momoh Gbetuwa,
- Odia Ikponmwosa,
- Danny A. Asogun,
- Peter O. Okokhere,
- Onikepe A. Follarin,
- John S. Schieffelin,
- Kelly R. Pitts,
- Joan B. Geisbert,
- Peter C. Kulakoski,
- Russell B. Wilson,
- Christian T. Happi,
- Pardis C. Sabeti,
- Sahr M. Gevao,
- S. Humarr Khan,
- Donald S. Grant,
- Thomas W. Geisbert,
- Erica Ollmann Saphire,
- Luis M. Branco,
- Robert F. Garry
Affiliations
- James E. Robinson
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Kathryn M. Hastie
- Department of Immunology and Microbial Science, Scripps Research Institute
- Robert W. Cross
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- Rachael E. Yenni
- Department of Microbiology and Immunology, Tulane University School of Medicine
- Deborah H. Elliott
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Julie A. Rouelle
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Chandrika B. Kannadka
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Ashley A. Smira
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Courtney E. Garry
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Benjamin T. Bradley
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Haini Yu
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Jeffrey G. Shaffer
- Department of Biostatistics and Bioinformatics, Tulane School of Public Health and Tropical Medicine
- Matt L. Boisen
- Corgenix, Inc.
- Jessica N. Hartnett
- Department of Microbiology and Immunology, Tulane University School of Medicine
- Michelle A. Zandonatti
- Department of Immunology and Microbial Science, Scripps Research Institute
- Megan M. Rowland
- Zalgen Labs, LLC
- Megan L. Heinrich
- Zalgen Labs, LLC
- Luis Martínez-Sobrido
- Department of Microbiology and Immunology, University of Rochester
- Benson Cheng
- Department of Microbiology and Immunology, University of Rochester
- Juan C. de la Torre
- Department of Immunology and Microbial Science, Scripps Research Institute
- Kristian G. Andersen
- Department of Immunology and Microbial Science, Scripps Research Institute
- Augustine Goba
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Mambu Momoh
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Mohamed Fullah
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Michael Gbakie
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Lansana Kanneh
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Veronica J. Koroma
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Richard Fonnie
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Simbirie C. Jalloh
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Brima Kargbo
- Ministry of Health and Sanitation
- Mohamed A. Vandi
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Momoh Gbetuwa
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Odia Ikponmwosa
- Department of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital
- Danny A. Asogun
- Department of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital
- Peter O. Okokhere
- Department of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital
- Onikepe A. Follarin
- Department of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital
- John S. Schieffelin
- Department of Pediatrics, Section of Infectious Disease, Tulane University School of Medicine
- Kelly R. Pitts
- Corgenix, Inc.
- Joan B. Geisbert
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- Peter C. Kulakoski
- Autoimmune Technologies, LLC, 1010 Common St #1705
- Russell B. Wilson
- Autoimmune Technologies, LLC, 1010 Common St #1705
- Christian T. Happi
- Department of Medicine, Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital
- Pardis C. Sabeti
- Department of Organismic and Evolutionary Biology, Center for Systems Biology, Harvard University
- Sahr M. Gevao
- Department of Medicine, University of Sierra Leone
- S. Humarr Khan
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Donald S. Grant
- Viral Hemorrhagic Fever Program, Kenema Government Hospital
- Thomas W. Geisbert
- Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston
- Erica Ollmann Saphire
- Department of Immunology and Microbial Science, Scripps Research Institute
- Luis M. Branco
- Zalgen Labs, LLC
- Robert F. Garry
- Department of Microbiology and Immunology, Tulane University School of Medicine
- DOI
- https://doi.org/10.1038/ncomms11544
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 14
Abstract
Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.
